WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Jeryl L. Hilleman net worth and biography

Jeryl Hilleman Biography and Net Worth

Director of NovoCure

Jeryl Hilleman became a director of Novocure in July 2018. Ms. Hilleman recently retired from Intersect ENT, a medical device company with commercial products for the treatment of chronic sinusitis, where she served as Chief Financial Officer from 2014 to 2019. Prior to joining Intersect ENT, she was Chief Financial Officer of Amyris Inc., a multi-national, renewable products company based in California and Brazil, from 2008 to 2012. Ms. Hilleman was a member of the board of directors and chair of the audit committee at Xenoport Inc., from 2004 to July 2018. She also served as Chief Financial Officer of Symyx Technologies, Ocera and Cytel. She is also a director of Minerva Neurosciences. Ms. Hilleman holds an A.B. from Brown University and an MBA from the Wharton Graduate School of Business. She is a member of the 1999 class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.

What is Jeryl L. Hilleman's net worth?: The estimated net worth of Jeryl L. Hilleman is at least $472,749.20 as of June 20th, 2023. Ms. Hilleman owns 15,349 shares of NovoCure stock worth more than $472,749 as of December 21st. This net worth approximation does not reflect any other investments that Ms. Hilleman may own. Learn More about Jeryl L. Hilleman's net worth.
How do I contact Jeryl L. Hilleman?: The corporate mailing address for Ms. Hilleman and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected]. Learn More on Jeryl L. Hilleman's contact information.
Has Jeryl L. Hilleman been buying or selling shares of NovoCure?: Jeryl L. Hilleman has not been actively trading shares of NovoCure in the last ninety days. Most recently, Jeryl L. Hilleman sold 407 shares of the business's stock in a transaction on Friday, June 10th. The shares were sold at an average price of $69.61, for a transaction totalling $28,331.27. Following the completion of the sale, the director now directly owns 2,537 shares of the company's stock, valued at $176,600.57. Learn More on Jeryl L. Hilleman's trading history.
Who are NovoCure's active insiders?: NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Executive Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Pritesh Shah (Insider), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.
Are insiders buying or selling shares of NovoCure?: During the last twelve months, insiders at the medical equipment provider sold shares 10 times. They sold a total of 11,141 shares worth more than $188,910.17. The most recent insider tranaction occured on November, 1st when EVP Frank X Leonard sold 598 shares worth more than $9,532.12. Insiders at NovoCure own 6.3% of the company. Learn More about insider trades at NovoCure.
Information on this page was last updated on 11/1/2024.

Jeryl L. Hilleman Insider Trading History at NovoCure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/10/2022	Sell	407	$69.61	$28,331.27	2,537
12/18/2020	Sell	2,500	$166.40	$416,000.00	3,400

Jeryl L. Hilleman Buying and Selling Activity at NovoCure

NovoCure Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Today's Range

Now: $30.80

$30.33

$31.52

50 Day Range

MA: $21.12

$15.18

$33.41

2 Week Range

Now: $30.80

$11.70

$34.13

Volume

1,820,699 shs

Average Volume

1,336,846 shs

Market Capitalization

$3.33 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75